Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include...
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Frontiers Media S.A.
2023-09-01
|
| Sarja: | Frontiers in Oncology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1213297/full |